Skip to main content
Premium Trial:

Request an Annual Quote

Rheonix Awarded SBIR Grant to Complete Development of HIV Assay

NEW YORK (GenomeWeb) – Rheonix today said it received a Small Business Innovation Research Phase I Fast-Track grant to complete the development of its fully automated self-confirming assay for the simultaneous detection of HIV/AIDS antibodies and viral RNA in a single specimen.

The grant from the National Institutes of Health is for six months and $189,646. Ithaca, NY-based Rheonix said it anticipates being awarded a follow-on 18-month, $1.5 million Phase II award.

The assay to be developed will simplify HIV testing and eliminate the need for multiple visits to a healthcare provider by a patient, Rheonix said. The firm has worked with researchers at New York University to develop a dual assay that can perform the initial test and the confirmatory test simultaneously on the same specimen.

Under the terms of the grant, Rheonix and NYU will continue collaborating on the complex benchtop assay as it is converted to Rheonix's Chemistry and Reagent Device (CARD) system, a fully automated molecular testing system that performs sample extraction, purification, amplification, and detection.

"By automating the entire process in a small, portable device, resource-limited regions will have their first-ever opportunity to perform simultaneous serological testing and molecular confirmation for HIV," Richard Montagna, Rheonix senior vice president for scientific and clinical affairs, said in a statement. He is the principal investigator on the grant.

In December, Rheonix announced a $14 million private financing directed at remodeling its existing space and adding a new headquarters to its physical operations, enabling it to scale up manufacturing capabilities and capacity as the company began production of the cartridges for the CARD system.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.